1. Serologic characteristics of oxaliplatin antibodies in 15 patients with drug-induced immune hemolytic anemia
- Author
-
Valentine Fihman, Tan Ngoc Nguyen, Isabelle Vinatier, Elodie Maenulein, and Julia Moh Klaren
- Subjects
Drug ,Hemolytic anemia ,Adult ,Male ,medicine.medical_specialty ,Colorectal cancer ,media_common.quotation_subject ,Immunology ,Antineoplastic Agents ,030204 cardiovascular system & hematology ,Gastroenterology ,Antibodies ,Serology ,Immune Hemolytic Anemia ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Immunology and Allergy ,Humans ,media_common ,Aged ,biology ,business.industry ,Albumin ,Hematology ,Middle Aged ,medicine.disease ,Oxaliplatin ,biology.protein ,Female ,Anemia, Hemolytic, Autoimmune ,Antibody ,business ,030215 immunology ,medicine.drug - Abstract
BACKGROUND Oxaliplatin, a third-generation platinum derivative is commonly used in combination treatment of metastatic colorectal cancer. Since 2008, it is the second most common cause of drug-induced immune hemolytic anemia (DIIHA) investigated in our laboratory. STUDY DESIGN AND METHODS Samples from fifteen patients including nine (60%) with intravascular hemolysis, suspected of having DIIHA were studied for the presence of anti-oxaliplatin. Direct antiglobulin tests (DATs) and tests with oxaliplatin-treated red blood cells (RBCs) or untreated and enzyme-treated RBCs in the presence of oxaliplatin were performed. A pool of normal AB sera with no unexpected antibodies was used as a control for nonimmunologic protein adsorption (NIPA). RESULTS Eleven (73%) of the fifteen patients had antibodies to oxaliplatin that reacted with drug-treated RBCs and untreated RBCs in the presence of drug by tube and/or gel method. Lower-titer reactivity (
- Published
- 2020